

Neurological Biomarkers Market for Alzheimers and Parkinsons Diseases - Global Opportunity Analysis and Industry Forecast, 2018-2025

<https://marketpublishers.com/r/N319E9DD516EN.html>

Date: June 2018

Pages: 90

Price: US\$ 5,370.00 (Single User License)

ID: N319E9DD516EN

Abstracts

The neurological biomarkers market for Alzheimer's disease generated a revenue of \$2,636.7 million in 2017, registering a CAGR of 11.1% from 2018 to 2025. On the other hand, neurological biomarkers market for Parkinson's disease is expected to reach \$2,457.4 million by 2025, registering a CAGR of 8.0%. Alzheimer's is included under dementia-associated conditions, and patients suffering from Alzheimer's face short-term memory loss, cognitive issues, and issues regarding behavior. In addition, Alzheimer is considered to be the most common form of dementia, and is known to account for the majority of the total dementia cases across the globe.

On the contrary, Parkinson's disease is the second most common neurodegenerative disorder across the globe. Patients suffering from Parkinson's disease face progressive deterioration of motor function that occurs over a period of time due to the loss of brain cells that produce dopamine. In spite of being the second most common neurodegenerative disorder (after Alzheimer's), the market for this disease is relatively small, as the definite cause and treatment is unknown. This has opened up new avenues for the use neurological biomarkers. The neurological biomarkers market for Alzheimer's and Parkinson's diseases is studied across the U.S., EU5, rest of Europe, China, Asia-Pacific, and rest of the world (ROW).

KEY BENEFITS

The study provides an in-depth analysis of the neurological biomarkers market, with current trends and future estimations regarding Alzheimer's and Parkinson's.

A quantitative analysis from 2017 to 2025 is discussed to enable the

stakeholders to capitalize on the prevailing market opportunities.

Strategies recorded by the key players are analyzed thoroughly to understand the competitive outlook of the market.

Porter's Five Forces model is expected to interpret the bargaining power of suppliers & buyers, threat of new entrants & substitutes, and competition among the key players.

KEY MARKET SEGMENTS

By Region

U.S.

EU5

Rest of Europe

China

Asia-Pacific

Row

KEY MARKET PLAYERS

Abbott Laboratories

Myriad RBM

Proteome Sciences

Thermo Fisher Scientific

Athena Diagnostics

Immunarray Pvt. Ltd.

Quanterix Corporation

Diagenic ASA

Psynova Neurotech

Bio-Rad Laboratories

The other players in the value chain include (profiles not included in the report)

Qiagen

AbaStar MDx

Acumen Pharmaceuticals

Abiant

Alseres Pharmaceuticals

Athena Diagnostics

Banyan Biomarkers

ProteoSys AG

Contents

CHAPTER 1: INTRODUCTION

- 1.1. Report description
- 1.2. Key benefits for stakeholders
- 1.3. Key market segments
- 1.4. Research methodology
 - 1.4.1. Secondary research
 - 1.4.2. Primary research
 - 1.4.3. Analyst tools & models
 - 1.4.4. Key assumptions
 - 1.4.5. Key experts

CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

- 3.1. Market definition and scope
- 3.2. Top winning strategies
- 3.3. Overall Diagnostic Market Size
 - 3.3.1. Total diagnostic market size by diagnostic techniques
- 3.4. Incidence, Mortality, Diagnosis Rate, Prevalence Rate and Treatment Rate for Alzheimers And Parkinsons Disease
 - 3.4.1. Incidence rate
 - 3.4.2. Mortality
 - 3.4.3. Diagnosis rate
 - 3.4.4. Prevalence rate
 - 3.4.5. Treatment rate
- 3.5. Porters five forces analysis
- 3.6. Market dynamics
 - 3.6.1. Drivers
 - 3.6.1.1. Increasing focus on developing cost-effective biomarker testing
 - 3.6.1.2. Rising demand for non-invasive diagnostic techniques for Alzheimers and Parkinsons
 - 3.6.1.3. Increase in the adoption of neurological biomarkers in clinical trials
 - 3.6.2. Restraints

- 3.6.2.1. Stringent government regulations
- 3.6.2.2. Emerging ethical issues regarding early diagnosis of Alzheimers and Parkinsons
- 3.6.3. Opportunity
 - 3.6.3.1. Rise in the demand for personalized medicine

CHAPTER 4: ALZHEIMER'S DISEASE BIOMARKERS MARKET, BY REGION

- 4.1. Overview
 - 4.1.1. Market size and forecast
- 4.2. U.S.
 - 4.2.1. Key market trends and opportunities
 - 4.2.2. Market size and forecast
- 4.3. EU5
 - 4.3.1. Key market trends and opportunities
 - 4.3.2. Market size and forecast
- 4.4. Rest of Europe
 - 4.4.1. Key market trends and opportunities
 - 4.4.2. Market size and forecast
- 4.5. China
 - 4.5.1. Key market trends and opportunities
 - 4.5.2. Market size and forecast
- 4.6. Asia-Pacific
 - 4.6.1. Key market trends and opportunities
 - 4.6.2. Market size and forecast
- 4.7. Rest of World (ROW)
 - 4.7.1. Key market trends and opportunities
 - 4.7.2. Market size and forecast

CHAPTER 5: PARKINSONS DISEASE BIOMARKERS MARKET, BY REGION

- 5.1. Overview
 - 5.1.1. Market size and forecast
- 5.2. U.S.
 - 5.2.1. Key market trends and opportunities
 - 5.2.2. Market size and forecast
- 5.3. EU5
 - 5.3.1. Key market trends and opportunities
 - 5.3.2. Market size and forecast

5.4. Rest of Europe

5.4.1. Key market trends and opportunities

5.4.2. Market size and forecast

5.5. China

5.5.1. Key market trends and opportunities

5.5.2. Key market trends and opportunities

5.5.3. Market size and forecast

5.6. Asia-Pacific

5.6.1. Key market trends and opportunities

5.6.2. Market size and forecast

5.7. ROW

5.7.1. Key market trends and opportunities

5.7.2. Market size and forecast

List Of Tables

LIST OF TABLES

- TABLE 01. KEY EXPERTS, NEUROLOGICAL BIOMARKERS MARKET
- TABLE 02. TOTAL DIAGNOSTIC ALZHEIMER'S MARKET, BY DIAGNOSTIC TECHNIQUES, 2017-2025 (\$MILLION)
- TABLE 03. TOTAL DIAGNOSTIC PARKINSON'S MARKET, BY DIAGNOSTIC TECHNIQUES, 2017-2025 (\$MILLION)
- TABLE 04. STATISTICS FOR ALZHEIMER'S IN U.S.
- TABLE 05. STATISTICS FOR ALZHEIMER'S IN EU5
- TABLE 06. STATISTICS FOR ALZHEIMER'S IN REST OF EUROPE
- TABLE 07. STATISTICS FOR ALZHEIMER'S IN CHINA
- TABLE 08. STATISTICS FOR ALZHEIMER'S IN ASIA-PACIFIC
- TABLE 09. STATISTICS FOR ALZHEIMER'S IN REST OF WORLD
- TABLE 10. STATISTICS FOR PARKINSONS IN U.S.
- TABLE 11. STATISTICS FOR PARKINSONS IN EU5
- TABLE 12. STATISTICS FOR PARKINSONS IN REST OF EUROPE
- TABLE 13. STATISTICS FOR PARKINSONS IN CHINA
- TABLE 14. STATISTICS FOR PARKINSONS IN ASIA-PACIFIC
- TABLE 15. STATISTICS FOR PARKINSONS IN REST OF WORLD
- TABLE 16. NEUROLOGICAL BIOMARKERS MARKET FOR ALZHEIMERS, BY REGION, 2017-2025 (\$MILLION)
- TABLE 17. INDIVIDUALS DIAGNOSED WITH ALZHEIMER'S DISEASE IN EU5, 2012
- TABLE 18. HUNGARY ALZHEIMER'S DISEASE PREVALENCE, BY AGE GROUP
- TABLE 19. ESTIMATED COST INCURRED & NUMBER OF INDIVIDUALS WITH ALZHEIMERS DISEASE IN THE ASIA-PACIFIC REGION
- TABLE 20. PREVALENCE OF ALZHEIMER'S DEMENTIA IN LATIN AMERICA, 2013
- TABLE 21. NEUROLOGICAL BIOMARKERS MARKET FOR PARKINSONS, BY GEOGRAPHY, 2017-2025 (\$MILLION)
- TABLE 22. PREVALENCE OF PARKINSONS DISEASE IN ASIA-PACIFIC REGION, 2017
- TABLE 23. PREVALENCE OF PARKINSONS DISEASE IN ASIA-PACIFIC REGION, 2017

List Of Figures

LIST OF FIGURES

FIGURE 01. TOP WINNING STRATEGIES, BY YEAR, 2014-2018

FIGURE 02. TOP WINNING STRATEGIES, 2014-2018 (%)

FIGURE 03. TOP WINNING STRATEGIES, BY COMPANY, 2014-2018

FIGURE 04. DIAGNOSTIC MARKET SIZE FOR ALZHEIMERS, 2017-2025 (\$MILLION)

FIGURE 05. DIAGNOSTIC MARKET SIZE FOR PARKINSON'S, 2017-2025
(\$MILLION)

FIGURE 06. HIGH BARGAINING POWER OF SUPPLIERS

FIGURE 07. HIGH BARGAINING POWER OF BUYERS

FIGURE 08. MODERATE THREAT OF SUBSTITUTION

FIGURE 09. MODERATE THREAT OF NEW ENTRANT

FIGURE 10. MODERATE COMPETITIVE RIVALRY

FIGURE 11. DRIVERS, RESTRAINTS, AND OPPORTUNITY: NEUROLOGICAL
BIOMARKERS MARKET FOR ALZHEIMERS (AD) AND PARKINSONS (PD)
DISEASES

FIGURE 12. PROJECTED NUMBER OF INDIVIDUALS IN THE U.S. WITH
ALZHEIMERS, 2010 TO 2050

FIGURE 13. ALZHEIMER'S DISEASE BIOMARKERS MARKET IN U.S.

FIGURE 14. ALZHEIMER'S DISEASE BIOMARKERS MARKET IN EU5

FIGURE 15. ALZHEIMER'S DISEASE BIOMARKERS MARKET IN REST OF EUROPE

FIGURE 16. NUMBER OF INDIVIDUALS IN CHINA WITH ALZHEIMERS, 1990 TO
2010

FIGURE 17. ALZHEIMER'S DISEASE BIOMARKERS MARKET IN CHINA

FIGURE 18. ALZHEIMER'S DISEASE BIOMARKERS MARKET IN ASIA-PACIFIC

FIGURE 19. ALZHEIMER'S DISEASE BIOMARKERS MARKET IN ROW

FIGURE 20. PARKINSONS DISEASE BIOMARKERS MARKET IN U.S.

FIGURE 21. PARKINSONS DISEASE BIOMARKERS MARKET IN EU5

FIGURE 22. PARKINSONS DISEASE BIOMARKERS MARKET IN REST OF EUROPE

FIGURE 23. PARKINSONS DISEASE BIOMARKERS MARKET IN CHINA

FIGURE 24. PARKINSONS DISEASE BIOMARKERS MARKET IN ASIA-PACIFIC

FIGURE 25. PARKINSONS DISEASE BIOMARKERS MARKET IN ROW

I would like to order

Product name: Neurological Biomarkers Market for Alheimers and Parkinsons Diseases - Global Opportunity Analysis and Industry Forecast, 2018-2025

Product link: <https://marketpublishers.com/r/N319E9DD516EN.html>

Price: US\$ 5,370.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N319E9DD516EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

